Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

howed that microplasmin-treated patients had a statistically significant improvement in the level of damage to the blood brain barrier compared to placebo-treated patients, measured using the marker of matrix metalloproteinase (MMP). MMP activation plays a crucial role in the pathogenesis of brain edema and hemorrhagic transformation after ischemic stroke.

It remains ThromboGenics' intention that it will only move forward with the development of microplasmin for the treatment of stroke in cooperation with a partner. This view is based on both the risks and cost associated with the development of new stroke therapies, and the Company's desire to invest in its other attractive pipeline product candidates, including microplasmin in the treatment of back of the eye diseases.

Staphylokinase (THR-100)

ThromboGenics partner for the clinical development and commercialization of THR-100, Bharat Biotech, continues to work with the Indian authorities to gain the necessary approvals to begin a Phase III trial with this novel variant of Recombinant Staphylokinase. The initial trial will evaluate THR-100 for the treatment of acute myocardial infarction (AMI), or heart attack. Given the commercial strengths of Bharat in this market and the clinical advantages of THR-100, it is hoped that this novel product will quickly become the market leader for the thrombolytic treatment of heart attacks in India.

TB-403 - Working with Roche on this Potential Breakthrough Cancer Treatment

ThromboGenics, in conjunction with its partner BioInvent, has made good progress in transferring this novel anti-cancer agent to Roche following the strategic alliance signed in June 2008.

Following the successful completion of the initial Phase I study, the parties have begun a Phase Ib trial with TB-403 in end-stage cancer patients. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Albany, NewYork (PRWEB) September 01, 2014 ... Pharma, Biotech and Diagnostics report provides comprehensive understanding ... and agreements entered into by the worlds leading ... detailed understand and analysis of how and why ... flexibility of a prospective partner’s negotiated deals terms ...
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
Breaking Biology Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... Researcher Provides Extensive Experience In Molecular DiagnosticsSALT LAKE ... company revolutionizing spine care through the development of ... Macina, Ph.D., has joined the executive management team ... and Development. Dr. Macina will report directly to ...
... Feb. 24 Innovative Biosensors, Inc., and ProGenTech ... diagnostics, today announced an agreement to jointly develop ... incorporate Innovative Biosensor,s proprietary Cellular Analysis and Notification ... cell-based approach for quickly detecting various pathogens, into ...
... the gene that ultimately controls the production of tooth ... to the repair of damaged enamel, a new concept ... of replacement teeth. , The gene, called Ctip2, is ... several functions - in immune response, and the development ...
Cached Biology Technology:Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Innovative Biosensors and ProGenTech Partner to Develop a Rapid Diagnostics System 2Innovative Biosensors and ProGenTech Partner to Develop a Rapid Diagnostics System 3Genetic discovery could lead to advances in dental treatment 2
(Date:9/2/2014)... September 2, 2014 A study published in ... of the American Academy of Child and Adolescent ... with a psychiatric diagnosis had an increased risk ... antipsychotics. , Using data from the nationwide Danish ... Ren Ernst Nielsen, Psychiatry, Aalborg University Hospital, Denmark, ...
(Date:9/2/2014)... of lithographic limestone is well known as a ... that area (for example, Archaeopteryx). Now, for the ... the French equivalent of these outcrops - discoveries ... known water treader. , Despite the abundance of ... have been obtained from the Late Kimmeridgian equivalents ...
(Date:9/1/2014)... in the U.S. has improved steadily in recent yearsspurred ... dietary quality remains poor and disparities continue to widen ... study from Harvard School of Public Health (HSPH). , ... that the extensive efforts by many groups and individuals ... but it also indicates that these efforts need to ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... in German . It,s a quick process, ... seconds, a laser beam has welded the casing and speedometer cover ... is a perfect weld seam scarcely visible to the naked eye. ... welding. What,s more: the resulting heat is confined to a minimal ...
... Columbia have been able to pinpoint more of the ... valuable compounds to the roasting process. Lead author ... the prevailing antioxidants present in dark roasted coffee brew ... high temperatures. Their findings will appear in ...
... of Zaragoza (UNIZAR) has studied precipitation trends in Spain,s ... The results show that precipitation has declined overall between ... of the rainy season. The rains are heavier in ... ,Since 1946, the average precipitation falling on Spanish hydrological ...
Cached Biology News:Laser welding in the right light 2Roasting coffee beans a dark brown produces valued antioxidants: UBC food scientists 2Rain in Spain is on the decline 2
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... gap filling, localized cloning of genomic DNA, ...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... is designed to deparaffinize and perform Heat ... paraffin-embedded tissue sections mounted on glass microscope ... paraffin at the high temperature used in ... of the paraffin by detergent. Formaldehyde fixation ...
Biology Products: